InMed Pharmaceuticals Inc. (NASDAQ:INM) Stock Short Interest Report for October

Posted by Brenda Bartman on Oct 28th, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) was the recipient of a large drop in short interest in October. As of October 15th, there was short interest totaling 6,634 shares, a drop of 80.5% from the September 30th total of 34,080 shares. Based on an average daily trading volume, of 34,106 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the shares of the company are short sold.

InMed Pharmaceuticals Price Performance

Shares of InMed Pharmaceuticals stock traded up $0.01 during trading hours on Wednesday, reaching $1.60. The company had a trading volume of 43,166 shares, compared to its average volume of 819,441. The firm has a market cap of $5.30 million, a PE ratio of -0.98 and a beta of 0.93. InMed Pharmaceuticals has a one year low of $0.57 and a one year high of $2.33. The business has a fifty day simple moving average of $1.38 and a 200 day simple moving average of $1.20.

Shares of InMed Pharmaceuticals are scheduled to split on the morning of Thursday, November 5th. The 2-1 split was recently announced. The newly issued shares will be payable to shareholders after the closing bell on Wednesday, November 4th.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last issued its earnings results on Wednesday, September 9th. The company reported ($1.43) EPS for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered InMed Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Check Out Our Latest Analysis on INM

Insiders Place Their Bets

In related news, major shareholder Adar1 Capital Management, Llc bought 54,256 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were purchased at an average cost of $1.30 per share, for a total transaction of $70,532.80. Following the completion of the purchase, the insider directly owned 883,761 shares in the company, valued at $1,148,889.30. The trade was a 6.54% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders acquired a total of 155,584 shares of company stock valued at $203,804 over the last 90 days. 0.85% of the stock is currently owned by insiders.

Hedge Funds Weigh In On InMed Pharmaceuticals

An institutional investor recently bought a new position in InMed Pharmaceuticals stock. Montanova Capital LLC acquired a new stake in shares of InMed Pharmaceuticals Inc. (NASDAQ:INM – Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 100,000 shares of the company’s stock, valued at approximately $155,000. Montanova Capital LLC owned about 3.02% of InMed Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 20.12% of the company’s stock.

About InMed Pharmaceuticals

(Get Free Report)

InMed Pharmaceuticals Inc is a Canada-based biotechnology company focused on developing pharmaceutical therapies that target the endocannabinoid system. The company’s research uses rare cannabinoids and cannabinoid analogs to address diseases with significant unmet medical needs, with an emphasis on neurological, ophthalmic and dermatological conditions.

InMed’s pipeline has included INM-901, an investigational program being developed for Alzheimer’s disease, as well as earlier programs targeting eye diseases such as glaucoma and age-related macular degeneration and the rare skin disorder epidermolysis bullosa.